| abstract |
REFERS TO PYRIDINONE DERIVATIVES OF FORMULA (I), WHERE R1 IS H, HALOGEN, NO2, ALKYL, AMONG OTHERS; R2 IS OH, PHENYL (C1-C6) ALCOXY, PHENYLOXY, PHENYL (C1-C6) ALKYL, AMONG OTHERS, THOSE WHICH ARE OPTIONALLY SUBSTITUTED BY HALOGEN, NR6R7, AMONG OTHERS; R3 IS H, HALOGEN, ALCOXYCARBONYL, AMONG OTHERS; R4 IS H, ALKYL OPTIONALLY REPLACED BY CO2R, OH, -C (O) NR6R7, AMONG OTHERS; R5 IS H, ARYLALKYL, PHENYL (C1-C6) ALKYL, ALKYL (C1-C6), INDOLYL, PYRIDYL, PYRIDAZINYL, AMONG OTHERS, OPTIONALLY REPLACED BY PHENYL (C1-C4) ALKYL, NROGENR9, H , ALCOXICARBONIL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 3-BROMO-4 - [(2,4-DIFLUOROBENZYL) OXY] -6-METHYL-1 - [(5-METHYLPYRAZIN-2-IL) METHYL] PYRIDIN-2 (IH) -ONE, ACID 4 - {[3-BROMO-4 - [(2,4-DIFLUOROBENZYL) OXY] -6- (HYDROXIMETHYL) -2-OXOPYRIDIN-1 (2H) -YL] METHYL] BENZOIC, 3 - {[3-BROMO-4 - [(2,4) -DIFLUOROBENZYL) OXY] -6-METHYL-2-OXOPYRIDIN-1 (2H) -YL] METHYL} -N-METHYL-1H-PYRAZOLE-5-CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OR MODULATORS OF MAP p38 KINASE, SO THEY ARE USEFUL IN THE TREATMENT OF INFLAMMATORY PROCESSES, ISCHEMIC DISEASES, CANCER THERAPIES |